SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- Protein Polymer Technologies,
Inc. (OTC Bulletin Board: PPTI) Chief Executive Officer William N. Plamondon
was interviewed by Nick Iyer of the Wall Street Network. A webcast and
transcript of the interview are available at http://www.wallst.net in the Audio
Interviews section for Over the Counter companies.
Plamondon discussed PPTI's upcoming corporate milestones and the recent
announcement of the company's intention to acquire Surgica Corporation, which
will allow PPTI to enter the growing embolization market. Surgica currently
markets three FDA-approved Polyvinyl Alcohol (PVA) product lines. According
to Plamondon, the acquisition of Surgica is expected to be completed in the
fourth quarter of 2005.
Owned and operated by Digital Wall Street, Inc., http://www.wallst.net is a
multimedia provider of commentary and news from North America's leading
companies, giving a direct link to the management of today's fastest-growing
companies through encompassing executive interviews and Sector Seminars. The
company offers both a free service to consumers and a premium, paid monthly
subscription to its members.
About Protein Polymer Technologies, Inc.
Protein Polymer Technologies, Inc. is a biotechnology company that
discovers and develops innovative therapeutic devices to improve medical and
surgical outcomes. The Company focuses on developing technology and products
to be used for soft tissue augmentation, tissue adhesives and sealants, wound
healing support and drug delivery devices. Protein Polymer Technologies
proprietary protein-based biomaterials are uniquely tailored to optimize
clinical performance and contain no human or animal components that could
potentially transmit or cause disease. The company is headquartered in San
Diego, California. For additional information about the company, please visit
http://www.ppti.com.
To date, PPTI has been issued twenty-six U.S. Patents on its core
technology with corresponding issued and pending patents in key international
markets.
This press release contains forward-looking statements that are based on
management's views and expectations. Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up. The reader is encouraged to refer
to the Company's 2004 Annual Report Form 10-KSB, and 10KSB/A and other recent
filings with the Securities and Exchange Commission, copies of which are
available from the Company, to further ascertain the risks associated with the
above statements.
SOURCE Protein Polymer Technologies, Inc.
 back to top
Related links:
http://www.ppti.com
CONTACT:
Erin Davis of Protein Polymer Technologies,
Inc., +1-858-558-6064, ext. 120; or Carole Boucard,
+1-954-370-2524, or Bryan deCastro, +1-631-495-9177, both of
Creative Public Relations, for Protein Polymer Technologies, Inc.
|
